PDS Biotechnology Corporation

NasdaqCM:PDSB Stock Report

Market Cap: US$54.5m

PDS Biotechnology Management

Management criteria checks 3/4

PDS Biotechnology's CEO is Frank Bedu-Addo, appointed in Mar 2019, has a tenure of 6.17 years. total yearly compensation is $2.26M, comprised of 26.4% salary and 73.6% bonuses, including company stock and options. directly owns 1.52% of the company’s shares, worth $829.04K. The average tenure of the management team and the board of directors is 2.2 years and 6.2 years respectively.

Key information

Frank Bedu-Addo

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage26.4%
CEO tenure6.2yrs
CEO ownership1.5%
Management average tenure2.2yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Jan 13

PDS Biotech jumps 13% as FDA clears further development of lead asset

Oct 03

PDS Biotechnology files for $150 mixed shelf offering

Aug 24

PDS Biotech spikes as panel backs continuation of cancer trial for lead asset

Aug 04

PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business

Jul 08
PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business

PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data

May 27

PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers

Feb 22

CEO Compensation Analysis

How has Frank Bedu-Addo's remuneration changed compared to PDS Biotechnology's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$2mUS$597k

-US$38m

Sep 30 2024n/an/a

-US$41m

Jun 30 2024n/an/a

-US$41m

Mar 31 2024n/an/a

-US$44m

Dec 31 2023US$5mUS$580k

-US$43m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023n/an/a

-US$48m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$2mUS$540k

-US$41m

Sep 30 2022n/an/a

-US$28m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$7mUS$475k

-US$17m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$815kUS$450k

-US$15m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$3mUS$356k

-US$7m

Compensation vs Market: Frank's total compensation ($USD2.26M) is above average for companies of similar size in the US market ($USD662.67K).

Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.

CEO

Frank Bedu-Addo (59 yo)

6.2yrs

Tenure

US$2,263,569

Compensation

Dr. Frank K. Bedu-Addo, Ph D., served as Interim Principal Financial Officer for PDS Biotechnology Corporation since September 30, 2021 until October 2021. Dr. Bedu-Addo was Chief Executive Officer of PDS...

Leadership Team

NamePositionTenureCompensationOwnership
Frank Bedu-Addo
President6.2yrsUS$2.26m1.52%
$ 829.0k
Stephan Toutain
Chief Operating Officer1yrUS$1.09m0%
$ 0
Kirk Shepard
Chief Medical Officer1.3yrsUS$1.35m0%
$ 0
Lars Boesgaard
Principal Financial & Accounting Officer and CFO1.4yrsno data0%
$ 0
Gregory Conn
Chief Scientific Officer6.2yrsUS$1.68m0.27%
$ 148.3k
Spencer Brown
Senior VP2.9yrsno data0%
$ 0
Janetta Trochimiuk
Controllerno datano datano data

2.2yrs

Average Tenure

59yo

Average Age

Experienced Management: PDSB's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Frank Bedu-Addo
President6.2yrsUS$2.26m1.52%
$ 829.0k
Richard Sykes
Independent Director6.2yrsUS$72.57k0.98%
$ 534.1k
Gregory Freitag
Independent Director6.2yrsUS$83.57k0.13%
$ 73.5k
Stephen Glover
Independent Chairman6.1yrsUS$114.07k0.17%
$ 94.6k
Jerold Woodward
Member of Scientific Advisory Boardno datano datano data
Kamil Jackson
Independent Director5.3yrsUS$84.57k0.026%
$ 14.1k
Mark Einstein
Member of Scientific Advisory Boardno datano datano data
Darron Brown
Member of Scientific Advisory Boardno datano datano data
Leaf Huang
Member of Scientific Advisory Boardno datano datano data
Samir Khleif
Member of Scientific Advisory Boardno datano datano data
Lisa Rohan
Chair of the Scientific Advisory Boardno datano datano data
Neil Gross
Member of Scientific Advisory Boardno datano datano data

6.2yrs

Average Tenure

63yo

Average Age

Experienced Board: PDSB's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 03:04
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PDS Biotechnology Corporation is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Mayank MamtaniB. Riley Securities, Inc.
Kalpit PatelB. Riley Securities, Inc.